IL4 and eosinophilic esophagitis: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases including EoE.13, 14, 15 LIBERTY EoE TREET was a 3-part, double-blind, placebo-controlled, phase 3 study that demonstrated improvements in histologic, symptomatic, endoscopic, and molecular aspects of the disease in adults and adolescents with EoE treated with dupilumab up to 52 weeks.16